GLP-1 Cost & Insurance Coverage: What You Need to Know in 2025

What Do GLP-1 Medications Cost Without Insurance?

The list prices for GLP-1 medications can be substantial, often representing a significant financial consideration for patients:

- Ozempic: Approximately $935 per month - Wegovy: Approximately $1,350 per month - Mounjaro: Approximately $1,060 per month - Zepbound: Approximately $1,060 per month - Rybelsus: Approximately $935 per month

These are approximate list prices and actual costs may vary by pharmacy and location. What you actually pay will depend heavily on your insurance coverage and any available savings programs.

Why Is Coverage Inconsistent?

Insurance coverage for GLP-1 medications varies dramatically based on several factors:

Indication Matters: Most insurance plans distinguish between medications prescribed for type 2 diabetes versus weight management. Coverage is generally more consistent for diabetes treatment, while weight management coverage remains less reliable.

Plan Variations: Even within the same insurance company, different plans may have different coverage policies. Employer-sponsored plans, individual marketplace plans, and government insurance programs all have distinct approaches.

Prior Authorization: Many plans require prior authorization, meaning your provider must demonstrate medical necessity before the medication is approved. This process can add time and administrative burden.

Step Therapy: Some plans require step therapy, meaning you must try other (usually less expensive) medications first before the GLP-1 will be covered.

Medicare and Medicaid Coverage Status

Medicare Part D: Historically, Medicare Part D has not covered medications prescribed solely for weight loss. However, Medicare may cover GLP-1 medications when prescribed for type 2 diabetes. The Inflation Reduction Act has begun to change the landscape of Medicare drug pricing, and ongoing policy discussions may affect future coverage.

Medicaid: Coverage varies significantly by state. Some state Medicaid programs cover GLP-1 medications for diabetes, but coverage for weight management is less common. Contact your state Medicaid office or managed care plan for specific information.

Employer Insurance Trends

There is a growing trend among employers to add or expand coverage for weight management medications, including GLP-1s. Some larger employers have recognized that treating obesity may reduce downstream healthcare costs associated with related conditions like diabetes, heart disease, and joint problems.

However, some employers have moved in the opposite direction, adding exclusions for these medications due to their high costs. The landscape is evolving rapidly.

If your employer plan does not currently cover weight management medications, it may be worth inquiring with HR about future plan changes or advocating for expanded coverage.

Manufacturer Savings Cards and Patient Assistance Programs

Pharmaceutical manufacturers offer programs that can significantly reduce costs for eligible patients:

Ozempic Savings Card (Novo Nordisk): Eligible commercially insured patients may pay as little as $25 per prescription. Not valid for patients on Medicare, Medicaid, or other government insurance.

Mounjaro Savings Card (Eli Lilly): Eligible patients may pay as little as $25 per fill for up to 12 fills.

Zepbound Savings Card (Eli Lilly): Similar savings available for eligible patients. Eli Lilly also offers a direct purchase program for patients without insurance coverage at specific price points.

Important: Savings card terms and availability change frequently. Always check manufacturer websites for current programs and eligibility requirements.

Compounded Semaglutide: Risks and Legal Status

Due to high costs and supply shortages, some patients have sought compounded versions of semaglutide from compounding pharmacies. Important considerations:

Legal Status: Under FDA regulations, compounding pharmacies can prepare copies of approved drugs when those drugs are on the official shortage list. When a shortage ends, the legal basis for compounding may change.

Safety Concerns: Compounded medications are not FDA-approved and may not meet the same quality, purity, and sterility standards as brand-name products. The FDA has issued warnings about potential risks.

Dosing Variability: Compounded products may have different concentrations or formulations than FDA-approved versions.

If you are considering compounded medications, discuss the risks and benefits thoroughly with your healthcare provider.

Telehealth Cost Comparison

Telehealth platforms have emerged as an alternative pathway to GLP-1 medications, often with different pricing structures:

Subscription Models: Some platforms charge monthly fees that may include consultations, monitoring, and sometimes the medication itself.

Consultation Fees: Other platforms charge per-visit fees for consultations with licensed providers.

Medication Costs: Some telehealth platforms have negotiated pricing for medications or work with specific pharmacies that may offer competitive rates.

What to Compare: When evaluating telehealth options, consider the total cost including consultations, monitoring, and medication costs. Also consider what services are included, such as ongoing support, dietary guidance, or regular check-ins.

Bottom Line

Navigating the cost of GLP-1 medications requires understanding your insurance coverage, exploring all available savings programs, and potentially considering alternative pathways like telehealth platforms.

Key strategies to reduce costs: - Check your insurance formulary and coverage policies - Apply for manufacturer savings programs if eligible - Compare prices at different pharmacies - Consider telehealth options and their total costs - Appeal insurance denials when appropriate - Ask about patient assistance programs if you have limited income

This article is for informational purposes only and does not constitute financial or medical advice. Consult with your healthcare provider and insurance company for specific guidance on your situation.